FDA

News

Idorsia first-in-class hypertension drug gets FDA okay

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist

News

Iclusig gets FDA nod as frontline therapy for rare leukaemia

Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le

News

CAR-T earlier use backing in multiple myeloma

CAR-Ts set to move earlier in multiple myeloma therapy

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broa

News

Geron leaps as ODAC backs its MDS drug imetelstat

Shares in Geron have almost doubled in after-hours trading after the FDA’s Oncological Drugs Advisory Committee (ODAC) voted by 12 to 2 in favour of its imetelstat therapy

News

FDA reviewer pokes holes in Geron’s MDS drug data

Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS) drug candidate imetelstat.

News

FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese.

Idorsia first-in-class hypertension drug gets FDA okay

Iclusig gets FDA nod as frontline therapy for rare leukaemia

CAR-Ts set to move earlier in multiple myeloma therapy

Geron leaps as ODAC backs its MDS drug imetelstat

FDA reviewer pokes holes in Geron’s MDS drug data

FDA clears Wegovy’s label to include heart health benefits

NICE changes stance on Genmab's cervical cancer drug

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks